1 Evaluation of a throat spray with lactobacilli in COVID-19 outpatients in a randomized, double-blind,

#### 2 placebo-controlled trial for symptom and viral load reduction

Ilke De Boeck<sup>1</sup>, Eline Cauwenberghs<sup>1</sup>, Irina Spacova<sup>1</sup>, Thies Gehrmann<sup>1</sup>, Tom Eilers<sup>1</sup>, Lize Delanghe<sup>1</sup>,
Stijn Wittouck<sup>1</sup>, Peter A. Bron<sup>1</sup>, Tim Henkens<sup>2</sup>, Imane Gamgami<sup>2</sup>, Alix Simons<sup>2</sup>, Ingmar Claes<sup>2</sup>, Joachim
Mariën<sup>3,4</sup>, Kevin K. Ariën<sup>3,5</sup>, Diana Bakokimi<sup>3</sup>, Katherine Loens<sup>6</sup>, Kevin Jacobs<sup>6</sup>, Margareta leven<sup>6</sup>,
Patricia Bruijning-Verhagen<sup>7</sup>, Peter Delputte<sup>6</sup>, Samuel Coenen<sup>8,9</sup>, Veronique Verhoeven<sup>8</sup>, Sarah
Lebeer<sup>15</sup>

8 <sup>1</sup>Research Group Environmental Ecology and Applied Microbiology, Department of Bioscience Engineering, University of 9 Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium. <sup>2</sup>YUN NV, Niel, Belgium. <sup>3</sup>Virology Unit, Department of 10 Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.<sup>4</sup> Evolutionary Ecology Group, Department of Biology, 11 University of Antwerp, Antwerp, Belgium.<sup>5</sup> Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. 12 <sup>6</sup>Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Antwerp, B-2610, Belgium. <sup>7</sup>Julius Centre for 13 Health Sciences and Primary Care, Department of Epidemiology, University Medical Centre Utrecht, Utrecht, The 14 Netherlands, <sup>8</sup>Family Medicine and Population Health (FAMPOP), University of Antwerp, Antwerp, Belgium. <sup>9</sup>Vaccine & 15 Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium

16 \$ corresponding author

#### 17 Abstract

Objectives: Primary care urgently needs treatments for COVID-19 patients because current options
 are limited, while these patients account for more than 90% of the people infected with SARS-CoV-2.

20 **Methods:** We evaluated a throat spray containing three *Lactobacillaceae* strains with broad antiviral 21 properties in a randomized double-blind placebo-controlled trial. Seventy-eight eligible COVID-19 22 patients were randomized to verum (n=41) and placebo (n=37) within 96 hours of positive PCR-based 23 SARS-CoV-2 diagnosis and per-protocol analysis was performed. Symptoms and severity were reported 24 daily via an online diary. Combined nose-throat swabs and dried blood spots were collected at regular 25 time points in the study. Results: The daily reported symptoms were highly variable, with no added benefit for symptom resolution in the verum group. Specific monitoring of the applied lactobacilli strains showed that they were detectable via microbiome (27%) and qPCR analysis (82%) of the verum group. Their relative abundances were also negatively correlated with the acute symptom score. At the end of the trial, a trend towards lower SARS-CoV-2 viral loads was observed for the verum group (2/30, 6.7% positive) compared to the placebo group (7/27, 26% positive) (p = 0.07).

32 Conclusions: Despite a trend towards lower SARS-CoV-2 viral loads at the end of the trial and a negative 33 correlation between relative abundances of the applied lactobacilli in the microbiome and acute 34 symptoms, we did not observe a significant effect on overall symptom score for the verum group. This 35 suggests that studies with earlier application of the spray in larger study populations are needed to 36 further assess application potential.

#### 37 Introduction

38 During the COVID-19 pandemic, most research and clinical trials on treatment options have been 39 conducted in hospitalized patients. This especially applies to intervention studies, which are routinely executed in a hospital setting in critically ill patients. However, only 10-20% of COVID-19 patients need 40 41 medical care in hospitals [1]. While these numbers vary depending on the dominating SARS-CoV-2 42 variant, this means that the majority of COVID-patients have mild to moderate symptoms, are not 43 hospitalized, and depend only on treatments such as antiflogistics and analgesics [1,2]. Nevertheless, 44 these milder cases exert a significant burden on healthcare professionals in primary care [2,3]. In 45 addition, asymptomatic and presymptomatic transmission is the main driver for to others [4]. 46 Respiratory viral infections can have severe health consequences due to imbalanced immune 47 activation and bacterial co-infections associated with airway tissue disruption and severe inflammation [5]. This clearly shows the urge for more treatment and/or prevention options in COVID-19 48 49 outpatients, which can improve different aspects of the disease: symptom relieve, transmission 50 reduction and decreased hospitalization.

51 Microbiome or probiotic therapy is an emerging alternative treatment option for respiratory viral 52 diseases based on the potential multifactorial action of beneficial bacteria in the airways [6]. While 53 oral administration of such microbiome therapeutics or probiotics remains most common [7], this 54 route relies on systemic effects to ameliorate respiratory infections. Also during the current COVID-19 55 pandemic, oral administrations targeting the gut have already been explored [8–10]. Alternatively, 56 topical application of rationally-selected probiotics in the airways might offer several advantages [11], 57 as this could lead to direct blocking or inhibition of respiratory viruses [12], and direct immune 58 modulation at the site of infection and inflammation [13,14]. Indeed, the probiotic definition is not 59 limited to the gut [15]. We recently developed a microbiome-modulating throat spray with three 60 Lactobacillaceae strains that were selected based on their safety and in vitro multifactorial modes of 61 action on the key aspects of viral infection and disease, and their ability to thrive in the human 62 respiratory tract of healthy volunteers [16]. Yet, microbiome therapy with live bacteria has several 63 challenges, such as formulation and selection of target patient population.

Here, we evaluated the clinical potential of this throat spray with *Lacticaseibacillus casei* AMBR2, *Lacticaseibacillus rhamnosus* GG, and *Lactiplantibacillus plantarum* WCFS1 against COVID-19 in a randomized, double-blind, placebo-controlled trial in COVID-19 outpatients exhibiting mild-tomoderate symptoms. Specifically, we monitored impact on symptom severity, time to improvement, viral load, anti-SARS-CoV-2 antibodies and the respiratory microbiome in an out-of-hospital setting. This trial relied on self-sampling and included collection of combined nose-throat swabs, fingerprick blood samples and reporting of symptom and severity via an online diary.

71 Methods

Clinical trial design: A double-blind, placebo-controlled clinical trial was performed with a microbiome
 throat spray in COVID-19 outpatients within 96 hours after a positive PCR test in government facilities
 (see more details in supplementary methods). Approval was obtained from the committee of medical
 Ethics (UZA/UAntwerpen, B3002021000018 and NCT04793997). Informed consent was obtained from

all participants prior to inclusion. Verum and placebo sprays were supplied by Yun NV (Niel, Belgium)
(supplementary methods). Randomization occurred in blocks of six patients with stratification for age
and gender and was done by the responsible clinicians (see supplementary methods for more details).

79 Study procedures: Patients were asked to use the verum spray or placebo for 14 days, with one week 80 of follow-up, and filled in an online diary via Qualtrics (Qualtrics, Provo, UT, USA) (detailed description 81 in Figure S1). Ten common COVID-19 symptoms were monitored, according to [17]. Different symptom 82 summary scores were compared between the verum and placebo groups, and time to improvement was evaluated based on the timepoint when participants reached their symptomatic tipping point 83 (supplementary methods). Combined nose/throat swabs for microbiome analysis, determination of 84 85 SARS-CoV-2 viral loads and detection of administered Lactobacillaceae strains via qPCR and MiSeq 86 amplicon sequencing were self-sampled, as well as blood fingerprick samples (dried blood spots) to 87 analyze SARS-CoV-2 IgG antibodies (Figure S1 and supplementary methods).

**Outcomes:** The primary clinical outcome of this trial was the change in severity of COVID-19 infection symptoms after using the microbiome spray. The secondary study outcomes included: (i) Change in duration (time to improvement) of COVID-19 infection symptoms after using microbiome spray, (ii) Change in absolute level of SARS-CoV-2 particles after using microbiome spray, (iii) Change in absolute numbers of specific bacterial pathogens after using microbiome spray, and (iv) Change in microbiome of nose/throat region after using microbiome spray.

Finally, some explorative (post-hoc) analyses were included: (i) relation of viral load with reported symptoms, (ii) colonization of the administered strains in the airways and (iii) correlation of the microbiome with several variables.

97 **Statistical analyses:** Per protocol analysis was performed on participants that completed the study and 98 provided samples on all timepoints. Standardized scores (z scores) were used for the analysis of the 99 primary outcome. The distributions of the severity score for four different symptom summary scores 100 (see supplementary methods) on every day between both treatment groups were compared. Kaplan 101 meier survival analysis was performed using the R survival package. The symptomatic tipping point 102 was taken as the event, and the time until occurrence was tested in the different treatment groups. 103 Differences between symptom scores in covid-positive and -negative participants (based on PCR) were 104 tested using a random effect model, symptom  $\sim$  covid + (1|participant). P-values were adjusted for 105 multiple testing using Bonferroni. Differential bacterial abundances between treatment groups were tested with a random effect model with CLR(ra) ~ treatment + plate + qubit\_score + library\_size + 106 107 (1|participant), where CLR(ra) is the centered-log-ratio transformed relative abundance of a given 108 bacteria, and plate, qubit\_score and library size constitute technical confounders. Effect sizes for the 109 treatment group were calculated for timepoints T2 and T3, at which the participants were using the 110 spray.

#### 111 Results

# Set-up of a placebo-controlled intervention trial in mild-to-moderate COVID-19 patients and assessment of study compliance and self-sampling

The trial was conducted from February 24, 2021 to April 30, 2021 at the University of Antwerp. Seventy-eight eligible patients were randomized, of which 41 were allocated to the verum spray and 37 to the placebo spray. Figure 1 depicts patient recruitment and enrollment. Fourteen participants dropped out during the trial (7 verum, 7 placebo; reasons in Figure 1) and per protocol analysis of the remaining participants that provided samples on all timepoints was conducted. Patient demographics, reported symptoms at enrollment, and time between positive PCR test and start of intervention are shown in Table 1.

121 The sprays were overall well-tolerated, but participants in both study groups often reported 122 unpleasant taste (mainly verum group) or texture (verum and placebo) of the spray. Also for the online 123 diaries, the compliance was high: the median number of completed diaries was 20/21 days, with 31.3% 124 of the study population showing full compliance, with filling in the diary every days. The compliance of the self-sampling was 80.5% (509/632) for the combined nose/throat swabs, and 83.5% (132/158) for
the fingerprick blood samples.

## 127 Monitoring of symptoms in primary- care patients and impact of the microbiome-throat spray on 128 symptom severity and time to improvement

Symptoms at the start of the study are shown in Table 1. Cough (68%), runny/blocked nose (70%), headache (65%) and fatigue (75%) were most frequently reported. The average total symptom score at start of the study was 13.4 ± 8.6 in the verum group and 15.2 ± 9.3 in the placebo group (difference not significant) (Table S1).

133 Severity of the symptoms was evaluated between both treatment groups over the study via the 134 distribution of the different severity scores (total, URT, acute and symptom) at every day (see also 135 Table S1). The same tendency for the verum and placebo group was observed with no significant 136 differences (Figure 2A-D). Independent of treatment, raw symptoms scores showed high inter- and 137 intra-individual fluctuation patterns (Figure S2), and scores were therefore propagated, smoothened 138 and standardized (Figure S3). Furthermore, time to improvement was not significantly different 139 between treatment groups and log odds (cox regression) were  $0.125 \pm 0.3$ ,  $-0.003 \pm 0.3$ ,  $0.111 \pm 0.3$ , 140 0.58 ± 0.3 for total, system, URT and acute scores, respectively (Figure 2E-H). Over the entire study 141 population, 59% of the individuals (independent of treatment) still experienced symptoms after 21 142 days. At this three-week timepoint, 5% reported acute symptoms, 39% systemic symptoms and 41% 143 URT symptoms.

#### 144 Impact of the microbiome spray on SARS-CoV-2 viral loads and relation with symptoms

At the start of the trial, 4/34 participants in the verum group and 3/30 participants in the placebo group had a negative RT-qPCR result despite testing positive less than 96h earlier. After one week, 73% of the participants in the verum group and 77% in placebo group tested positive (p = 1, Fisher's exact test), while after 2 weeks this was 17% and 32%, respectively (p = 0.22, Fisher's exact test). At the end of the trial, 2/30 (6.7%) patients in the verum group and 7/27 (26%) patients in the placebo group still tested positive (p = 0.07, Fisher's exact test) (Figure 3A, 3B). Independent of the intervention, all
symptoms had a strong correlation with being SARS-CoV-2 positive (Table S2), although several
symptoms, such as cough, nasal symptoms and fatigue, were still reported upon a negative PCR result
(Figure 3C).

Analysis of self-collected fingerprick blood samples showed that at the start of the study, only 4/61 enrolled COVID-19 patients were positive or borderline positive for anti-SARS-CoV-2 IgG based on antibody reactivity against the receptor-binding domain (RBD), nucleocapsid (NCP) and spike proteins (S1S2) of SARS-CoV-2 [18] (Figure 3D). After 3 weeks, 51/61 patients were positive or borderline positive for anti-SARS-CoV-2 IgG, without significant differences between placebo and verum groups (p = 0.71, Chi-square test).

#### 160 Impact of SARS-CoV-2 infection on the upper airway microbiome

161 Principal coordinates analysis (PCoA) showed no major shifts in the overall nose/throat microbial 162 composition for the time points nor for the microbiome treatment (Figure 4A). However, specific 163 effects on abundances of certain taxa were observed. When focusing on abundances of the amplicon 164 sequence variants (ASVs) of the Lactobacillaceae strains administered with the throat spray, significant 165 differences were observed between verum and placebo groups at different time points with mean 166 relative abundances for the L. casei ASV, L. plantarum ASV and L. rhamnosus ASV in the verum group 167 found to be 1.6%, 1.3% and 0.5%, respectively, over the entire study (Figure 4B, Table S3). In the 168 placebo group, these numbers were below 0.01% for all three ASVs (see also Table S3). Prevalences 169 (presence) based on MiSeq data were 38.6%, 28% and 13.4% for the L. casei ASV, L. plantarum ASV 170 and L. rhamnosus ASV, respectively, while this was 10.5%, 7% and 2% in the placebo group, pointing 171 at the fact that the related taxa to the applied lactobacilli are also endogenously present, but in low 172 numbers. Therefore, the presence of the specifically applied Lactobacillaceae strains was also 173 confirmed via qPCR with clear difference between verum (on average detected in 82% of the study 174 population) and placebo (on average 21%) and also between the estimated CFU/ml counts of the three strains, in a range of 10<sup>8</sup> CFU/ml for *L. casei* AMBR2, 10<sup>7</sup> CFU/ml for *L. plantarum* WCFS1, and 10<sup>6</sup>
CFU/ml for *L. rhamnosus* GG, in line with the concentrations in which they were added in the throat
spray (Figure 4C, Table S4).

178 Next, we correlated the relative abundances of a selection of ASVs belonging to important airway 179 genera (Rothia, Dolosigranulum, Streptococcus, Staphylococcus, Haemophilus, Moraxella, and 180 Lactobacillus) with treatment, severity scores and viral load across all timepoints and made a further 181 selection based on the ASVs that showed the highest effect sizes (Figure 4D). Lactobacillus ASV 1 182 L. casei/paracasei/zeae), 2 L. (potentially Lactobacillus (potentially 183 fabifermentans/paraplantarum/pentosus/plantarum), and Lactobacillus ASV 4 (potentially L. 184 rhamnosus) have a strong significant enrichment in the verum group, which was true across all 185 timepoints and more pronounced on treatment timepoints only (Figure 4D). In addition to the 186 deliberately added bacteria, other ASVs were positively correlated with the verum group, including 187 Moraxella ASV 4 (M. lacunata), Rothia ASV 14 (R. amarae) and several commensal Streptococcus ASVs 188 (among others thermophilus, rubneri and sanguinis). On the other hand, negative correlations with 189 treatment were observed with the strongest effect sizes for Dolosigranulum ASV 1 (D. pigrum), 190 Streptococcus ASV 7 (S. gordonii) and Streptococcus ASV 6 (S. crispatus/oligofermentans/sinensis).

Finally, positive and negative correlations between the symptom scores and specific taxa, with moderate effect sizes were found (Figure 4D). Of interest, a significant negative correlation was found for the ASVs corresponding to the applied lactobacilli and the acute symptom score, indicating that application of these lactobacilli could result in less acute symptoms. *Dolosigranulum* ASV 1, another lactic acid bacterium, had a negative correlation with the acute symptom score severity and even with the total score. Conversely, *Haemophilus* ASV 3 (*H. aegyptius*) positively correlated with the different symptom scores. Viral load did not have significant associations with specific taxa.

198 Discussion

199 We evaluated the use of a specifically formulated topical microbiome throat spray with three selected 200 members of the Lactobacillaceae in a placebo-controlled, remote self-sampling study in COVID-19 201 outpatients. Detailed microbiome and qPCR analysis showed a detection of the applied strains in the 202 verum group in on average 82% of the participants based on qPCR with estimated concentrations 203 between 10<sup>6</sup>-10<sup>8</sup> CFU/ml. Analysis of the self-reported symptoms showed a patient-dependent disease 204 progression with high intra- and interindividual variations and no significant effects of the intervention 205 on the primary outcome in this rather small study population. However, a trend of faster decreasing 206 viral loads was observed in the verum group compared to placebo, with after three weeks 6.7% and 207 26% of participants remaining positive based on RT-qPCR testing, respectively (p = 0.07). This remains 208 to be substantiated in follow-up studies.

209 A first key finding of the study was the personal fluctuations of COVID symptoms, which we could 210 document quite detailed thanks to online questionnaires that were developed within the Rapid 211 European COVID-19 Emergency Response research (RECOVER) project [17]. Another study with daily 212 monitoring of symptoms for two weeks also recently reported that the natural course of COVID-19 213 disease is highly patient-dependent and variable [19]. This highly fluctuating disease pattern and 214 subjective self-evaluation of the symptom scores also complicates studies on treatments for COVID-19 215 symptoms. For instance, no effects of oral azithromycin in outpatients on the absence of self-reported 216 symptoms after 14 days as primary outcome were observed in a study with 263 patients [20]. This was 217 confirmed in the large open-label, multi-arm PRINCIPLE trial for the azithromycin group (n = 2265) [21]. 218 On the other hand, inhaled budesonide showed positive effects in COVID-19 outpatients at risk aged 219 50-65 years (n = 4700) with a benefit in time to self-reported recovery of 2.9 days for patients in the 220 budesonide group compared to usual care group [22]. While probiotic trials in COVID-19 outpatients 221 are scarce compared to drug interventions, at least two recent studies reported symptom 222 improvement. After intranasal administration of *Lactococcus lactis* W136 (n = 23), the proportion of 223 patients with fatigue was lower in the verum group than placebo on day 7 (p = 0.02). In addition, 224 patients in the verum group had reduced loss of sense of smell on day 9 (p = 0.03) and reduced

shortness of breath on day 8 (p = 0.02) and day 12 (p = 0.04) compared to placebo [23]. However, it
should be noted that the authors did not report any correction for multiple testing in this study, which
is also not yet peer reviewed. In another larger trial (n = 300) with an oral probiotic mixture of *L. plantarum* strains and *Pediococcus acidilactici* KABP021, patients in the verum group reported fewer
days of fever, cough, headache, body aches and shortness of breath [8].

230 Our results on the viral loads at day 21 are promising and in line with our previously reported in vitro 231 data, where we showed that the microbiome members that were selected for the throat spray show 232 clear antiviral effects against coronaviruses under controlled in vitro study set-ups [16]. In the trial with 233 the oral probiotic L. plantarum strains and Pediococcus acidilactici KABP021, a significantly larger 234 reduction in nasopharyngeal viral load was observed in the verum group at day 15 and day 30 ( $p < 10^{-10}$ 235 0.001) [8]. Our data on viral loads should be further substantiated, because our study had several 236 limitations. In addition to the already discussed high biological variation of COVID-19 disease 237 progression and the rather small study population, we also experienced a suboptimal timepoint of 238 intervention. The start point appeared too late after disease onset. This has also been observed in 239 other trials with antivirals for respiratory infections [24,25]. For local applications of probiotics or 240 microbiome therapeutics [6] compared to oral applications such as [8], it is especially important that 241 the antiviral bacteria are provided early enough in the viral infection process, considering the more 242 local mode of action. Oral probiotics target the gut and systemic immunity to reduce symptoms in later 243 phases [26]. Here, we had to rely on the standard government PCR testing procedures in Belgium, 244 resulting in a delay between testing and inclusion. Most participants started within 2-5 days after their 245 first symptoms, when the viral loads were highest. A study design with a more preventive set-up might 246 be more suitable to evaluate a microbiome throat spray with a mode of action early in the viral 247 infection process. Moreover, we also observed that most patients still experienced symptoms at the 248 end of the monitoring (5% still reported acute symptoms, 39% systemic symptoms and 41% URT 249 symptoms), so that follow-up work with any potential therapeutic or nutritional interventions in 250 outpatients preferably extents the follow-up period for the patients to evaluate long COVID effects.

251 Our finding of reduced viral loads also suggests some to-be-validated potential to reduce transmission 252 to household members and other high-risk contacts. In a prospective cohort study conducted in the 253 Netherlands and Belgium, it was shown that secondary transmission within households occurred in 254 44.4% of the households, mostly very early after the index patient was positive [17]. Moreover, it might 255 be useful for future studies to stratify potential responders and non-responders based on the 256 microbiome (e.g. exclude patients with high relative abundances of lactic acid bacteria Dolosigranulum 257 because of the negative correlation found here with treatment), which is currently not standard in 258 clinical trials with microbiome therapeutics or probiotics. Moreover, an alternative formulation such 259 as a nose spray instead of the used throat spray, might be more favorable, since SARS-CoV-2 receptors 260 are highly expressed in nasal epithelium, and the alpha variant that was dominant during the study has 261 been shown to primarily target the nose [27]. In addition, based on in-house previous research, the 262 selected lactobacilli have several beneficial modes of action such as antimicrobial and 263 immunomodulatory properties, as well as barrier enhancing effects in the nasal epithelium [28–30]. 264 However, this might also depend on the virus variant that is most dominant, because the current SARS-265 CoV-2 Omicron (B.1.1.529) variant seems to target the throat as the first or main site with high viral 266 loads.

267 Since our study was one of the few in mild-to-moderate COVID patients outside the hospital and mostly 268 based on self-sampling, we also generated relevant information irrespective of the treatment 269 evaluated. In addition to the already mentioned intrapersonal fluctuations and interpersonal 270 variations of disease symptoms, we also observed a robust detection of SARS-CoV-2 virus in self-271 collected combined nose/throat swabs. This exemplifies that a self-sampling approach for these types 272 of samples is feasible, in line with the previously demonstrated effectivity of SARS-CoV-2 detection in 273 oropharyngeal swabs collected by self-sampling during early infection to other read-outs and sample 274 types [31]. Furthermore, our results indicate robust detection of IgG against the SARS-CoV-2 RBD, NCP 275 and S1S2 antigens in self-collected dry blood spot samples, allowing detection of positive cases without 276 the need for blood collection by healthcare professionals. Remote study set-ups with self-sampling and online questionnaires can thus represent a promising set-up for studies in COVID-19 outpatients
and other infectious diseases. Collecting samples without involvement of a third party could reduce
exposure, expand testing capacities, and minimize the burden on the hospitals and general
practitioners during the COVID-19 pandemic [31,32].

Taken together, our study suggests that the microbiome throat spray might have beneficial effects via lowering nose/throat viral loads, potentially resulting in less virus transmission. Future studies are required to investigate this transmission to for instance household members. We also believe that a more preventive set-up is advised for the evaluation of this microbiome therapy, for instance for highrisk contacts.

#### 286 Funding

287 IDB and IS were supported by grants from Research Foundation - Flanders (FWO postdoctoral grants 288 12S4222N and 1277222N) and IDB also by a small research grant of the University of Antwerp (BOF KP 289 43829). EC is supported by the iBOF grant POSSIBL. TH, AS, and IC were supported by a research grant 290 from Flanders Innovation & Entrepreneurship (HBC.2020.2923). KKA was supported by the Research 291 Foundation - Flanders (G0G4220N) and by an intramural grant (a subsidy from the Department of 292 Economy, Science and Innovation (EWI) from the Flemish Government). LD was supported a Baekeland 293 mandate from Flanders Innovation & Entrepreneurship (HBC.2020.2873). SL, TH and TE were 294 supported by the European Research Council grant (Lacto-Be 26850). The application of the real-time 295 duplex PCR for the detection of SARS-CoV-2 and RNAseP was funded through the RECOVER project 296 (European Commission under H2020 call SC1-PHE-CORONAVIRUS-2020).

#### 297 Acknowledgements

We would like to thank Sam Van Goethem for his advice on the study packages and logistics for the home sampling. We also would like to thank all GPs that helped with the recruitment and all study participants that participated in this trial. Furthermore, we want to thank the LebeerLab team, in particular Ines Tuyaerts, Nele Van de Vliet, Leen Van Ham, Marianne van den Broek, Sarah Ahannach,

302 Vincent Greffe, and Marie Legein. Finally, we would like to thank Biobank Antwerpen (Antwerp,
303 Belgium; ID: BE 71030031000).

#### 304 Conflict of interest statement

IDB, IS, IC, TH and SL are inventors on a patent application (BE2021/5643) related to this work. IC, TH, IG and AS are working at YUN NV (www.yun.be) who formulated the spray for this study. SL is a member of the scientific advisory board of YUN NV. The PhD research of LD is currently funded by VLAIO through a Baekeland mandate in collaboration with YUN NV. YUN was not involved in the clinical study design or data analysis of this work. PAB is a consultant for multiple companies in the food and health industry, but they were not involved in this manuscript. The remaining authors have no conflicts of interest to declare related to this work.

#### 312 Data availability statement

All data produced in the present study are available upon reasonable request to the authors or will bedeposited online after publication

#### 315 References

321

316 [1] Dugas M, Grote-Westrick T, Vollenberg R, Lorentzen E, Brix T, Schmidt H, et al. Less severe

317 course of COVID-19 is associated with elevated levels of antibodies against seasonal human

318 coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1). Int J Infect Dis 2021;105:304–6.

319 https://doi.org/10.1016/J.IJID.2021.02.085.

320 [2] Verhoeven V, Tsakitzidis G, Philips H, Van Royen P. Impact of the COVID-19 pandemic on the

core functions of primary care: Will the cure be worse than the disease? A qualitative

- interview study in Flemish GPs. BMJ Open 2020;10. https://doi.org/10.1136/bmjopen-2020039674.
- Wanat M, Hoste M, Gobat N, Anastasaki M, Böhmer F, Chlabicz S, et al. Transformation of
   primary care during the COVID-19 pandemic: experiences of healthcare professionals in eight

- European countries. Br J Gen Pract 2021;71. https://doi.org/10.3399/BJGP.2020.1112.
  Shi Q, Hu Y, Peng B, Tang XJ, Wang W, Su K, et al. Effective control of SARS-CoV-2 transmission
- 328 in Wanzhou, China. Nat Med 2020 271 2020;27:86–93. https://doi.org/10.1038/s41591-020329 01178-5.
- 330 [5] Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host
- 331 Response to SARS-CoV-2 Drives Development of COVID-19. Cell 2020;181:1036-1045.e9.
- 332 https://doi.org/10.1016/J.CELL.2020.04.026.
- 333 [6] Spacova I, De Boeck I, Bron PA, Delputte P, Lebeer S. Topical Microbial Therapeutics against

334 Respiratory Viral Infections. Trends Mol Med 2021;27:538–53.

- 335 https://doi.org/10.1016/J.MOLMED.2021.03.009.
- Hao Q, Dong BR, Wu T. Probiotics for preventing acute upper respiratory tract infections.
  Cochrane Database Syst Rev 2015. https://doi.org/10.1002/14651858.CD006895.pub3.
- 338 [8] Gutiérrez-Castrellón P, Gandara-Martí T, Abreu Y Abreu AT, Nieto-Rufino CD, López-Orduña E,
- 339 Jiménez-Escobar I, et al. Probiotic improves symptomatic and viral clearance in Covid19
- 340 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes
- 341 2022;14.
- 342 https://doi.org/10.1080/19490976.2021.2018899/SUPPL\_FILE/KGMI\_A\_2018899\_SM2404.D
   343 OCX.
- Ceccarelli G, Borrazzo C, Pinacchio C, Santinelli L, Innocenti G Pietro, Cavallari EN, et al. Oral
  Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr 2021.
  https://doi.org/10.3389/fnut.2020.613928.
- 347 [10] d'Ettorre G, Ceccarelli G, Marazzato M, Campagna G, Pinacchio C, Alessandri F, et al.
- 348 Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as
- 349 Complementary Therapeutic Strategy to Avoid the Progression of COVID-19. Front Med

350

2020;7:389. https://doi.org/10.3389/fmed.2020.00389.

- 351 [11] De Boeck I, Spacova I, Vanderveken OM, Lebeer S. Lactic acid bacteria as probiotics for the
- 352 nose? Microb Biotechnol 2021;14:859–69. https://doi.org/10.1111/1751-7915.13759.
- 353 [12] Chen H-W, Liu P-F, Liu Y-T, Kuo S, Zhang X-Q, Schooley RT, et al. Nasal commensal
- 354 Staphylococcus epidermidis counteracts influenza virus. Sci Rep 2016;6:27870.
- 355 https://doi.org/10.1038/srep27870.
- 356 [13] Spacova I, Petrova MI, Fremau A, Pollaris L, Vanoirbeek J, Ceuppens JL, et al. Intranasal
- 357 administration of probiotic *Lactobacillus rhamnosus* GG prevents birch pollen-induced allergic
- 358 asthma in a murine model. Allergy 2019;74:100–10. https://doi.org/10.1111/all.13502.
- 359 [14] Youn HN, Lee DH, Lee YN, Park JK, Yuk SS, Yang SY, et al. Intranasal administration of live
- Lactobacillus species facilitates protection against influenza virus infection in mice. Antiviral
   Res 2012;93:138–43. https://doi.org/10.1016/j.antiviral.2011.11.004.
- 362 [15] Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific
- 363 Association for Probiotics and Prebiotics consensus statement on the scope and appropriate
- 364 use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506–14.
- 365 https://doi.org/10.1038/nrgastro.2014.66.
- 366 [16] Spacova I, De Boeck I, Cauwenberghs E, Delanghe L, Bron PA, Henkens T, et al. Live

367 biotherapeutic throat spray for respiratory virus inhibition and interferon pathway induction.

368 BioRxiv 2022:2022.01.25.477549. https://doi.org/10.1101/2022.01.25.477549.

- 369 [17] Verberk J, de Hoog M, Westerhof I, van Goethem S, Lammens C, Ieven M, et al. Transmission
- 370 of SARS-CoV-2 within households: A prospective cohort study in the Netherlands and Belgium
- 371 Interim results. MedRxiv 2021:1–18. https://doi.org/10.1101/2021.04.23.21255846.
- 372 [18] Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating SARS-
- 373 CoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild

- 374 COVID-19 cases using a Luminex bead-based assay. J Virol Methods 2021;288:114025.
- 375 https://doi.org/10.1016/J.JVIROMET.2020.114025.
- 376 [19] Rodebaugh TL, Frumkin MR, Reiersen AM, Lenze EJ, Avidan MS, Miller JP, et al. Acute
- 377 Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and
- 378 Over Time. Open Forum Infect Dis 2021;8. https://doi.org/10.1093/OFID/OFAB090.
- 379 [20] Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of Oral
- 380 Azithromycin vs Placebo on COVID-19 Symptoms in Outpatients with SARS-CoV-2 Infection: A
- 381 Randomized Clinical Trial. JAMA J Am Med Assoc 2021;326:490–8.
- 382 https://doi.org/10.1001/jama.2021.11517.
- 383 [21] Butler CC, Dorward J, Yu LM, Gbinigie O, Hayward G, Saville BR, et al. Azithromycin for
- 384 community treatment of suspected COVID-19 in people at increased risk of an adverse clinical
- 385 course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.

386 Lancet 2021;397:1063–74. https://doi.org/10.1016/S0140-6736(21)00461-

387 X/ATTACHMENT/22EF69BB-C37F-48F3-BD10-92D88E328CCF/MMC1.PDF.

- 388 [22] Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide
- 389 for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a

390 randomised, controlled, open-label, adaptive platform trial. Lancet 2021.

391 https://doi.org/10.1016/S0140-6736(21)01744-X.

392 [23] Endam LM, Tremblay C, Filali A, Desrosiers MY. INTRANASAL APPLICATION OF LACTOCOCCUS

- 393 LACTIS W 136 BACTERIA EARLY IN SARS-Cov-2 INFECTION MAY HAVE A BENEFICIAL
- 394 IMMUNOMODULATORY EFFECT: A PROOF-OF-CONCEPT STUDY. MedRxiv 2021.
- 395 [24] Ison MG, Hayden FG. Antiviral Agents Against Respiratory Viruses. Infect Dis (Auckl)

396 2017:1318. https://doi.org/10.1016/B978-0-7020-6285-8.00154-4.

397 [25] Roymans D, Alnajjar SS, Battles MB, Sitthicharoenchai P, Furmanova-Hollenstein P, Rigaux P,

- et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun 2017.
- 399 https://doi.org/10.1038/s41467-017-00170-x.
- 400 [26] Kanauchi O, Andoh A, AbuBakar S, Yamamoto N. Probiotics and Paraprobiotics in Viral
- 401 Infection: Clinical Application and Effects on the Innate and Acquired Immune Systems. Curr
- 402 Pharm Des 2018. https://doi.org/10.2174/1381612824666180116163411.
- 403 [27] Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry
- 404 factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat
- 405 Med 2020. https://doi.org/10.1038/s41591-020-0868-6.
- 406 [28] De Boeck I, van den Broek MFL, Allonsius CN, Spacova I, Wittouck S, Martens K, et al.
- 407 Lactobacilli Have a Niche in the Human Nose. Cell Rep 2020;31:107674.
- 408 https://doi.org/10.1016/J.CELREP.2020.107674.
- 409 [29] Martens K, Boeck I De, Jokicevic K, Kiekens F, Farré R, Vanderveken OM, et al.
- 410 Lacticaseibacillus casei AMBR2 Restores Airway Epithelial Integrity in Chronic Rhinosinusitis
- 411 With Nasal Polyps. Allergy, Asthma, Immunol Res 2021;13.
- 412 [30] De Rudder C, Garcia-Tímermans C, De Boeck I, Lebeer S, Van de Wiele T, Calatayud Arroyo M.
- 413 Lacticaseibacillus casei AMBR2 modulates the epithelial barrier function and immune
- 414 response in a donor-derived nasal microbiota manner. Sci Rep 2020;10:1–16.
- 415 https://doi.org/10.1038/s41598-020-73857-9.
- 416 [31] Würstle S, Spinner CD, Voit F, Hoffmann D, Hering S, Weidlich S, et al. Self-sampling versus
- 417 health care professional-guided swab collection for SARS-CoV-2 testing. Infect 2021 2021;1:1–
- 418 8. https://doi.org/10.1007/S15010-021-01614-9.
- 419 [32] Majam M, Msolomba V, Scott L, Stevens W, Marange F, Kahamba T, et al. Self-Sampling for
- 420 SARS-CoV-2 Diagnostic Testing by Using Nasal and Saliva Specimens: Protocol for Usability and
- 421 Clinical Evaluation. JMIR Res Protoc 2021;10. https://doi.org/10.2196/24811.

### **Table 1: Patient demographics and baseline characteristics by treatment group.** Due to missing values of 4

425 participants that did not complete or fill in the intake survey, this table is based on data from 60 participants.

	Verum (n = 33 )	Placebo (n = 27)
Age (years) [mean, stdv]	42 ± 12	43 ± 12
Sex (female) [n, %]	21 [62%]	19 [63%]
Body Mass Index (BMI, kg/m <sup>2</sup> ) [mean, stdv]	26.6 ± 4.8	26.1 ± 5.5
• Of which obesity (BMI >30)	4 [12%]	5 [19%]
Smoker (yes) [n, %]	4 [12%]	5 [19%]
Employment in		
• Patient care [n, %]	1 [3%]	1 [4%]
• Children care [n, %]	2 [6%]	1 [4%]
• Teaching [n, %]	7 [21%]	5 [19%]
Inhalation allergy [n, %]	15 [45%]	7 [26%]
Lung disease (asthma, COPD)	3 [9%]	4 [15%]
Cardiac disease (yes) [n, %]	2 [6%]	0 [0%]
Immune disorder (yes) [n, %]	1 [3%]	1 [4%]
Diabetes (yes) [n, %]	1 [3%]	1 [4%]
Hypertension [n, %]	3 [9%]	4 [15%]
Days from positive PCR test [median, range]	1 [-1,3]	1 [0-4]
Days since onset of symptoms [median, range]	3 [1-18]	2 [1-11]
Fever (yes) [n, %]	5 [15%]	7 [26%]
Cough (yes) [n, %]	24 [73%]	17 [63%]
Sore throat (yes) [n, %]	13 [39%]	9 [33%]
Runny/blocked nose (yes) [n, %]	20 [61%]	22 [81%]
Shortness of breath (yes) [n, %]	7 [21%]	7 [26%]
Headache (yes) [n, %]	21 [64%]	18 [67%]
Loss of smell and taste (yes) [n, %]	8 [24%]	5 [19%]
Muscle pain (yes) [n, %]	17 [52%]	15 [56%]
Chills (yes) [n, %]	13 [39%]	7 [26%]
Fatigue (yes) [n, %]	25 [76%]	20 [74%]
Diarrhea (yes) [n, %]	2 [6%]	2 [7%]



Figure 1: CONSORT flowchart for patient recruitment and enrollment. \* Excluded for not meeting the inclusion
criteria (mostly because time from positive PCR test was > 96 hours, often when people contacted the study
coordinator in response to the press release message) or declined to participate after first contact with study
coordinator. Of note, for the analysis of SARS-CoV-2 viral loads with RT-qPCR, 4 participants in the verum group
and 3 participants in placebo already had a negative PCR test at T1 of our study. Hence, for this analysis, 30
participants and 27 participants were analyzed for verum and placebo, respectively.



Figure 2: Symptom severity and time to improvement. Severity of the reported symptoms (A-D) was evaluated based on different scoring systems: Total score (A), URT score (B), system score (C) and acute score (D). Results are shown as standardized scores (z-score) to adjust for the highly subjective self-evaluation. Time to improvement (E-H) was also evaluated for the 4 scoring systems between both study groups. Survival analysis showed no significant differences for all tested scores between placebo and verum (p > 0.1).



440

441 Figure 3: Viral loads in combined nose/throat swabs. A) SARS-CoV-2 viral loads in combined nose-throat swabs 442 determined via PCR at start (T1), after 1 week (T2), after 2 weeks (T3) and after 3 weeks/end of the study (T4). 443 Results are shown as Ct values. B) Heatmap showing presence or absence of SARS-CoV-2 based on positive PCR 444 test. Each vertical line represents one participant. C) Relation between self-reported symptoms and SARS-CoV-445 2 viral load. D) Presence of anti-SARS-CoV-2 IgG antibodies in the blood of COVID-19 patients (COV) at the start 446 (T1) and at the end (T4) of study comprising 3 weeks in between. Data for treatment groups verum and placebo 447 is depicted as number of participants positive, borderline or negative for anti-SARS-CoV-2 IgG as part of the total 448 number of participants per treatment group per time point. Only participants with blood samples available at 449 both T1 and T4 were included in this analysis. 450



451

452 Figure 4: Microbial community composition in the airways (A), detection of the administered Lactobacillaceae 453 strains (B-C) and correlation of treatment and symptom scores with bacterial taxa (D). A) PCoA was used to 454 visualize the microbiome composition in combined nose/throat swabs for each treatment group and at the 455 different timepoints. T1 = start, T2 = after 1 week, T3 = after 2 weeks, and T4 = end trial. B) Relative abundances 456 of L. casei ASV, L. plantarum ASV and L. rhamnosus ASV between placebo and verum. See also Table S2 for mean 457 relative abundances for all ASVs at the different timepoints and statistics. C) qPCR with species-specific primers 458 for L. rhamnosus GG, L. casei AMBR2 and L. plantarum WCFS1 was used to estimate the CFU/ml counts. Based 459 on the standard curve, the detection limit was estimated to be at 10<sup>3</sup> CFU/ml. D) Correlation of treatment and 460 symptom scores with bacterial taxa across all timepoints in the study. For the treatment, the correlation was also 461 evaluated for treatment time only.